Details of the Active Pharmaceutical Ingredient (API)
General Information of API (ID: D00507) | |||||
---|---|---|---|---|---|
Name |
Panobinostat
|
||||
Synonyms |
Click to Show/Hide the Synonyms of This API
Panobinostat; 404950-80-7; LBH589; LBH-589; Farydak; Faridak; LBH 589; Panobinostat (LBH589); (E)-N-Hydroxy-3-(4-(((2-(2-methyl-1H-indol-3-yl)ethyl)amino)methyl)phenyl)acrylamide; NVP-LBH-589; UNII-9647FM7Y3Z; LBH-589B; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; CHEBI:85990; 9647FM7Y3Z; 404950-80-7 (free base); (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide; NVP-LBH589; Farydak (TN); (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide; (2E)-N-Hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide; N-Hydroxy-3-[4-[2-(2-methyl-1H-indol-3-yl)ethylaminomethyl]phenyl]-2(E)-propenamide; (E)-N-hydroxy-3-(4-((2-(2-methyl-1H-indol-3-yl)ethylamino)methyl)phenyl)acrylamide; 2-Propenamide, N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-, (2E)-; Panobinostat [USAN:INN]; 2-Propenamide, N-hydroxy-3-(4-(((2-(2-methyl-1H-indol-3-yl)ethyl)amino)methyl)phenyl)-, (2E)-; N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide; PubChem19147; Panobinostat(LBH589); LBH589 - Panobinostat; Panobinostat (USAN/INN); cc-487; MLS006011216; NVP-LBH 589; SCHEMBL164801; SCHEMBL183197; CHEMBL483254; GTPL7489; SCHEMBL22773814; BDBM29589; CHEBI:93774; DTXSID40193506; EX-A169; BCPP000187; BDBM198124; LBH-589/Panobinostat /LBH589; AOB87727; BCP01816; LBH58,9NVP-LBH589,Panobinostat; ABP000143; MFCD09833242; NSC761190; ZINC22010649; AKOS005146046; ACN-025765; BCP9000844; CCG-208762; CS-0267; DB06603; EX-8456; NSC-761190; SB16464; (E)-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enehydroxamic acid; NCGC00263117-05; NCGC00263117-07; AC-28652; AM808102; AS-17046; BR-77283; HY-10224; QC-10419; SMR004702978; AB0007883; DB-025426; SW219369-1; EC-000.2287; A25218; D10319; W-5406; 139304-EP2270008A1; 139304-EP2292617A1; J-523585; Q7131441; BRD-K02130563-001-07-2; (E)-N-Hydroxy-3-[4-[[[2-(2-methyl-1H-indole-3-yl)ethyl]amino]methyl]phenyl]acrylamide; N-hydroxy-3 -[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide; N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide; (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Panobinostat;(E)-N-hydroxy-3-(4-((2-(2-methyl-1H-indol-3-yl)ethylamino)methyl)phenyl)acrylamide
|
||||
Clinical Status |
Approved
|
||||
Disease Indication | Multiple myeloma | ICD-11: 2A83 | [1] | ||
PubChem CID | |||||
Formula |
C21H23N3O2
|
||||
Canonical SMILES |
CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO
|
||||
InChI |
1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+
|
||||
InChIKey |
FPOHNWQLNRZRFC-ZHACJKMWSA-N
|
||||
Click to Show/Hide the Molecular Data (Structure/Property) of This API | |||||
Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=6918837"></iframe>
|
||||
3D MOL | 2D MOL | ||||
Physicochemical Properties | Molecular Weight | 349.4 | Topological Polar Surface Area | 77.2 | |
XlogP | 3 | Complexity | 474 | ||
Heavy Atom Count | 26 | Rotatable Bond Count | 7 | ||
Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 3 | ||
Full List of Drug Formulations (DFMs) Containing This API | ||||||
---|---|---|---|---|---|---|
Panobinostat 10 mg capsule | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Mannitol; Cellulose, microcrystalline; Starch, corn
|
|||||
Dosage Form | Oral Capsule | |||||
Company | Novartis Pharmaceuticals Corporation | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [2] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Panobinostat 15 mg capsule | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Mannitol; Cellulose, microcrystalline; Starch, corn
|
|||||
Dosage Form | Oral Capsule | |||||
Company | Novartis Pharmaceuticals Corporation | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [2] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Panobinostat 20 mg capsule | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Magnesium stearate; Mannitol; Cellulose, microcrystalline; Starch, corn
|
|||||
Dosage Form | Oral Capsule | |||||
Company | Novartis Pharmaceuticals Corporation | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [2] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Panobinostat Lactate eq 10mg base capsule | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Magnesium Stearate; Mannitol; Microcrystalline Cellulose; Pre-Gelatinized Starch; Gelatin; Titanium Dioxide; Fd&C Blue 1; Yellow Iron Oxide
|
|||||
Dosage Form | Capsule | |||||
Company | Secura | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
FD&C blue no. 1 | DIG Info | Solute carrier SLCO2B1 (Ki = 13 uM) | [4] | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [2] | |||
Gelatin | DIG Info | Mephenytoin 4-hydroxylase (EC50 = 20.5 uM) | [5] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Pregelatinized starch | DIG Info | Multidrug resistance protein 1 (Protein expression downregulation) | [3] | |||
Panobinostat Lactate eq 15mg base capsule | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Magnesium Stearate; Mannitol; Microcrystalline Cellulose; Pre-Gelatinized Starch; Gelatin; Titanium Dioxide; Yellow Iron Oxide; Red Iron Oxide
|
|||||
Dosage Form | Capsule | |||||
Company | Secura | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [2] | |||
Gelatin | DIG Info | Mephenytoin 4-hydroxylase (EC50 = 20.5 uM) | [5] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Pregelatinized starch | DIG Info | Multidrug resistance protein 1 (Protein expression downregulation) | [3] | |||
Panobinostat Lactate eq 20mg base capsule | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Magnesium Stearate; Mannitol; Microcrystalline Cellulose; Pre-Gelatinized Starch; Gelatin; Titanium Dioxide; Red Iron Oxide
|
|||||
Dosage Form | Capsule | |||||
Company | Secura | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [2] | |||
Gelatin | DIG Info | Mephenytoin 4-hydroxylase (EC50 = 20.5 uM) | [5] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Pregelatinized starch | DIG Info | Multidrug resistance protein 1 (Protein expression downregulation) | [3] | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.